Menu Menu

News

Topics
Featured
COVID-19 Research Pipeline

216,681

Registered/ Published

4,604

Registered

793

Published

8,000

Registered
As at 23 June 2023
FILTERED BY > Molnupiravir (Lagverio) Clear filter

Communique #76

2 December, 2022
Click for the latest news:
Communique

Taskforce updates molnupiravir guidance following PANORAMIC trial results

2 December, 2022
The Taskforce has incorporated the preliminary results of the PANORAMIC trial into the body of evidence for oral antiviral molnupiravir (Lagevrio). This large (25,783 participants) open-label randomised controlled...
News

Communique #68

22 July, 2022
Click for the latest Taskforce news: 
Communique

Update to recommendations for adults with mild COVID-19

21 July, 2022
To reflect changing language from ATAGI and to remove confusion among clinicians about what ‘up-to-date’ with vaccination means, the Taskforce has replaced this terminology across all relevant adult...
News

I’ve tested positive for COVID-19? What treatments are available?

9 March, 2022
  With several new drug treatments for people with mild COVID-19 now available, it can be tricky to know what your options are should you test positive to...
Explainer

Communique #59

7 March, 2022
Click for the latest Taskforce news:
Communique

Communique #58

18 February, 2022
Click for the latest Taskforce news:
Communique

Communique #57

3 February, 2022
Click for the latest Taskforce news:
Communique

Communique #56

31 January, 2022
Click for the latest Taskforce news:
Communique

Communique #55

17 December, 2021
Click for the latest Taskforce news:
Communique

Communique #51

15 October, 2021
WEEK IN REVIEW Updates to the Living Treatment Guidelines New recommendations New recommendation for Continuous positive airway pressure / High-flow nasal oxygen therapy The Hospital and Acute Care...
Communique